NDAINJECTIONINJECTABLE
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
UNASYN (ampicillin sodium and sulbactam sodium) by Pfizer is clinical pharmacology general immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam for injection, peak serum concentrations of ampicillin and sulbactam are attained. Approved for infections due to susceptible strains of the designated microorganisms in the conditions listed below, development of drug-resistant bacteria, maintain effectiveness of ampicillin and 5 more indications. First approved in 1986.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UNASYN is a fixed-dose combination injectable antibiotic containing ampicillin sodium and sulbactam sodium, approved in 1986. It works by inhibiting bacterial cell wall synthesis (ampicillin) while sulbactam prevents enzymatic degradation of ampicillin, extending its spectrum against beta-lactamase-producing organisms. It is administered intravenously or intramuscularly for susceptible bacterial infections.
$0.093MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D claims signals small branded team focused on hospital and specialty channels rather than primary commercial expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY General Immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam for injection, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent…
Worked on UNASYN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.